SCHEMBL2999609

SCHEMBL2999609

CCOC(=O)c1cn([C@H](CO)[C@@H](C)O)c2ccc(I)cc2c1=O

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.47
KMT2A Q03164 2/20 0.40
PTPN1 P18031 1/20 0.39
HPGD P15428 5/20 0.39
MAPT P10636 2/20 0.39
MEN1 O00255 1/20 0.39
THRB P10828 1/20 0.39
MAP2K2 P36507 1/20 0.38
MAP2K1 Q02750 1/20 0.38
POLB P06746 1/20 0.38
ALDH1A1 P00352 5/20 0.38
KDM4E B2RXH2 5/20 0.38
HSD17B10 Q99714 3/20 0.38
NPC1 O15118 1/20 0.37
TDP1 Q9NUW8 1/20 0.37
GLA P06280 1/20 0.36
GAA P10253 1/20 0.36
CNR1 P21554 1/20 0.36
CNR2 P34972 1/20 0.36
ALOX15 P16050 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13007926 0.93 LMNA (0.47) LMNAKMT2APTPN1HPGDMAPT
SCHEMBL3005280 0.91 LMNA (0.46) LMNAKMT2APTPN1HPGDMAPT
SCHEMBL13080458 0.91 LMNA (0.46) LMNAKMT2APTPN1HPGDMAPT
SCHEMBL2994052 0.88 LMNA (0.49) LMNAKMT2APTPN1HPGDMAPT
SCHEMBL13080446 0.88 LMNA (0.49) LMNAKMT2APTPN1HPGDMAPT
SCHEMBL3005361 0.87 LMNA (0.50) LMNAKMT2APTPN1HPGDMAPT
SCHEMBL3001658 0.87 LMNA (0.52) LMNAKMT2APTPN1HPGDMAPT
SCHEMBL13007929 0.85 LMNA (0.47) LMNAKMT2APTPN1HPGDMAPT
SCHEMBL13080449 0.85 LMNA (0.47) LMNAKMT2APTPN1HPGDMAPT
SCHEMBL2992856 0.85 LMNA (0.48) LMNAKMT2APTPN1HPGDMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8283361-B2 Heterocyclic urea derivatives and methods of use thereof ASTRAZENECA AB (SE) 2012-10-09 US disclosed
US-8283361-B2 Heterocyclic urea derivatives and methods of use thereof ASTRAZENECA AB (SE) 2012-10-09 US disclosed
US-20100190745-A1 HETEROCYCLIC UREA DERIVATIVES AND METHODS OF USE THEREOF ASTRAZENECA AB (SE) 2010-07-29 US disclosed
US-20100190745-A1 HETEROCYCLIC UREA DERIVATIVES AND METHODS OF USE THEREOF ASTRAZENECA AB (SE) 2010-07-29 US disclosed
US-20100190745-A1 HETEROCYCLIC UREA DERIVATIVES AND METHODS OF USE THEREOF ASTRAZENECA AB (SE) 2010-07-29 US disclosed
WO-2009147433-A1 HETEROCYCLIC UREA DERIVATIVES FOR THE TREATMENT OF BACTERIAL INFECTIONS ASTRAZENECA AB (SE) 2009-12-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100190745-A1 HETEROCYCLIC UREA DERIVATIVES AND METHODS OF USE THEREOF UROD, UMPS, SLC14A1 LMNA 2705/4885KMT2A 3820/4885PTPN1 4049/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.